Binding Determinants of Glycoprotein Hormone Receptors
糖蛋白激素受体的结合决定因素
基本信息
- 批准号:6995214
- 负责人:
- 金额:$ 33.6万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2005
- 资助国家:美国
- 起止时间:2005-01-01 至 2008-12-31
- 项目状态:已结题
- 来源:
- 关键词:binding sitescell linecell surface receptorschemical modelscircular dichroismenzyme linked immunosorbent assayfollicle stimulating hormonegel filtration chromatographyglycoproteinshormone binding proteinhormone receptorion exchange chromatographyleucineluteinizing hormonemolecular shapeprotein purificationreceptor bindingreceptor expressionsite directed mutagenesisultracentrifugation
项目摘要
DESCRIPTION (provided by applicant): The glycoprotein hormones (GpHs), luteinizing hormone (LH), follicle-stimulating hormone (FSH) and thyroid-stimulating hormone (TSH), regulate fertility and metabolism. Their receptors (GpHRs) are distinguished from most G protein-coupled receptors by the presence of large N-terminal extracellular hormone-binding domains (ECDs). Each ECD consists of nine leucine-rich repeats (LRRs), flanked by N-terminal and C-terminal cysteine-rich regions (NCR and CCR, respectively). The signal of specific hormone binding to the ECD is conveyed by its CCR to the heptahelical transmembrane region (TM). Mutations, activating or inactivating GpHR function, have been identified in hyperthyroidism, precocious puberty and pseudohermaphroditism; moreover, polymorphic variants of LH and FSH receptors have been shown to change the susceptibility to female infertility, breast cancer and risk of bone fractures. AIMS: 1. Identify common hormone-contact sites and key hormone-selective determinants in LRRs of GpHRs, 2. Identify residues in the cysteine-rich regions of GpHRs important for GpH binding and for conveying the binding signal to the TM, and 3. Determine the three-dimensional structure of GpH-GpHR complexes. METHODS: Domain exchange/site-directed mutagenesis, expression, hormone binding and cAMP-dependent reporter activity as readouts, molecular modeling, ECD protein expression, protein purification, crystallization, crystal structure determination. OUTCOME: The results of the proposed studies will increase our knowledge of the molecular mechanisms by which GpHRs recognize the 'correct' GpH, as well as the step-wise propagation of the signal to the TM following ligand binding. These data, in combination with the mutant 'gain-of-function' GpHRs, will be molded into a general model of GpHR activation, essential for the development of better treatment protocols and the rational design of drugs that change receptor activity. Moreover, these data may yield a better understanding of the etiology of different pathological states known for some GpH-GpHR pairs.
性状(由申请方提供):糖蛋白激素(GpHs)、促黄体生成素(LH)、促卵泡激素(FSH)和促甲状腺激素(TSH)调节生育力和代谢。它们的受体(GpHR)与大多数G蛋白偶联受体的区别在于存在大的N-末端胞外酶结合结构域(ECD)。每个ECD由9个富含亮氨酸的重复序列(LRR)组成,两侧分别是N-末端和C-末端富含半胱氨酸的区域(分别为NCR和CCR)。与ECD结合的特异性激素的信号通过其CCR传递到七螺旋跨膜区(TM)。突变,激活或失活GpHR功能,已被确定在甲状腺功能亢进症,性早熟和假两性畸形;此外,LH和FSH受体的多态性变体已被证明会改变女性不孕症,乳腺癌和骨折的风险的易感性。目标:1.确定常见的酶接触位点和关键酶选择性决定因素的LRR的GpHRs,2。鉴定GpHR的富含半胱氨酸的区域中的残基,所述残基对于GpH结合和将结合信号传递至TM是重要的,以及3.确定GpH-GpHR复合物的三维结构。方法:结构域交换/定点诱变、表达、激素结合和cAMP依赖性报告活性作为读数、分子建模、ECD蛋白表达、蛋白纯化、结晶、晶体结构测定。结果:所提出的研究的结果将增加我们的知识的分子机制,GpHRs识别“正确的”GpH值,以及逐步传播的信号的TM配体结合。这些数据与突变的“功能获得性”GpHR结合,将被塑造成GpHR激活的一般模型,这对于开发更好的治疗方案和合理设计改变受体活性的药物至关重要。此外,这些数据可能会产生一个更好的理解的病因学不同的病理状态已知的一些GpH-GpHR对。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
J DAVID PUETT其他文献
J DAVID PUETT的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('J DAVID PUETT', 18)}}的其他基金
Binding Determinants of Glycoprotein Hormone Receptors
糖蛋白激素受体的结合决定因素
- 批准号:
6855902 - 财政年份:2005
- 资助金额:
$ 33.6万 - 项目类别:
Binding Determinants of Glycoprotein Hormone Receptors
糖蛋白激素受体的结合决定因素
- 批准号:
7171597 - 财政年份:2005
- 资助金额:
$ 33.6万 - 项目类别:
Binding Determinants of Glycoprotein Hormone Receptors
糖蛋白激素受体的结合决定因素
- 批准号:
7332216 - 财政年份:2005
- 资助金额:
$ 33.6万 - 项目类别:
ENDORPHIN, PHENOTHIAZINE AND ENZYME SITES ON CALMODULIN
钙调蛋白上的内啡肽、吩噻嗪和酶位点
- 批准号:
3288115 - 财政年份:1985
- 资助金额:
$ 33.6万 - 项目类别:
ENDORPHIN, PHENOTHIAZINE AND ENZYME SITES ON CALMODULIN
钙调蛋白上的内啡肽、吩噻嗪和酶位点
- 批准号:
3288111 - 财政年份:1985
- 资助金额:
$ 33.6万 - 项目类别:
ENDORPHIN, PHENOTHIAZINE AND ENZYME SITES ON CALMODULIN
钙调蛋白上的内啡肽、吩噻嗪和酶位点
- 批准号:
3288116 - 财政年份:1985
- 资助金额:
$ 33.6万 - 项目类别:
相似海外基金
Establishment of a Mouse NK Cell Line for Analyzing Tumor Infiltration Processes and Developing a Preclinical Model for Cancer Immunotherapy.
建立小鼠 NK 细胞系,用于分析肿瘤浸润过程并开发癌症免疫治疗的临床前模型。
- 批准号:
23K06731 - 财政年份:2023
- 资助金额:
$ 33.6万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Proof of usefulness of PDX derived cell line
PDX 衍生细胞系的有用性证明
- 批准号:
23K06616 - 财政年份:2023
- 资助金额:
$ 33.6万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
A novel producer cell line for more efficient manufacturing of viral vector systems
用于更有效地制造病毒载体系统的新型生产细胞系
- 批准号:
10597799 - 财政年份:2023
- 资助金额:
$ 33.6万 - 项目类别:
Genestorian: a web application to document and trace genetic modifications in model organism and cell line collections.
Genestorian:一个网络应用程序,用于记录和追踪模型生物和细胞系集合中的遗传修饰。
- 批准号:
EP/Y024591/1 - 财政年份:2023
- 资助金额:
$ 33.6万 - 项目类别:
Fellowship
AI-Aided Tool for Day Zero Selection of High Performing Cells for Biopharma Cell Line Development
用于生物制药细胞系开发的高性能细胞零日选择的人工智能辅助工具
- 批准号:
10672364 - 财政年份:2022
- 资助金额:
$ 33.6万 - 项目类别:
Developing a stable cell line expressing recombinant sclerostin
开发表达重组硬化素的稳定细胞系
- 批准号:
10385037 - 财政年份:2022
- 资助金额:
$ 33.6万 - 项目类别:
Development of Natural Killer (NK) Cell Line-Derived Extracellular Vesicles as a New Treatment for Cancer
开发自然杀伤 (NK) 细胞系衍生的细胞外囊泡作为癌症的新治疗方法
- 批准号:
10383462 - 财政年份:2022
- 资助金额:
$ 33.6万 - 项目类别:
A cell culture management platform to improve biomedical reproducibility by combining cell line tracking, low-cost genetic analysis, and riskassessment
细胞培养管理平台,通过结合细胞系追踪、低成本遗传分析和风险评估来提高生物医学重现性
- 批准号:
10483063 - 财政年份:2022
- 资助金额:
$ 33.6万 - 项目类别:
Modulating expression of candidate genes to improve lentiviral vector production in stable cell line
调节候选基因的表达以提高稳定细胞系中慢病毒载体的产量
- 批准号:
2752732 - 财政年份:2022
- 资助金额:
$ 33.6万 - 项目类别:
Studentship
AI-Aided Tool for Day Zero Selection of High Performing Cells for Biopharma Cell Line Development
用于生物制药细胞系开发的高性能细胞零日选择的人工智能辅助工具
- 批准号:
10546865 - 财政年份:2022
- 资助金额:
$ 33.6万 - 项目类别: